The Scripps Institute for Translational Science is working with Aetna and Johnson & Johnson on trials of the iRhythm Zio patch and the Amiigo activity tracking device to try to find new ways to screen people at high risk for atrial fibrillation. Steven Steinhubl, head of the company's digital medical department, said that at the end of the trial, it was possible to learn in detail what is the right way to screen people at high risk for atrial fibrillation. Although other studies have found ways to detect atrial fibrillation, they want to find ways to detect more patients with atrial fibrillation through continuous monitoring. The Amiigo used in this test is a motion monitoring device. Steinhubl said that it was mainly because of the contract with Antai and Johnson & Johnson that Amiigo was used in response to multi-center trials in remote areas. The study, called Mobile Medical Screening Prevention Stroke (mSToPS), used 2,000 people in activity monitoring devices in the 6,000 population and 4,000 as observation controls. Patients were recruited through the Antai company network. The study population is a high-income population: women over the age of 65 or men over 55 have a history of heart disease, stroke or hypertension. Active participants will continue to observe for six months. All 2000 experimental group subjects were Zin a Zio patch, some of which used Amiigo devices. Steinhubl said that the purpose of wearing the Amiigo wristband is to explore whether it is possible to replace the ECG with pulse monitoring, allowing researchers to measure the user's heart rate and heart rate through passive and random all-weather monitoring. An unknown challenge is that researchers don't know how to effectively diagnose atrial fibrillation. Both can be compared by wearing a Zio sticker and Amiigo at the same time. He also said that Amiigo is similar to other wristband monitoring methods in that it monitors heart rate through the pulse. The main difference is that consumer wristband tracking devices do not have software and algorithms for detecting atrial fibrillation. So if the study suggests the expected results, the results are not limited to Amiigo, but can be used in other consumer wearable devices. The study is an open-ended approach that attempts to find the best way to capture asymptomatic atrial fibrillation, which is often tricky and only discovered when it causes heart disease. Steinhubl expects to publish preliminary findings next year. Compact Air Hose Reel,Retractable Air Hose Reel,Retractable Air Compressor Hose,Small Retractable Air Hose Reel NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.water-hose-reel.com
Scientists try to find an asymptomatic atrial fibrillation with wearable devices